Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007341
Chunk: 112

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 112
---
 Ordinary                              
 Shares (in the form of Depositary Shares) and which we are registering hereby. The warrants are subject to a beneficial ownership limitation  
 of 4.99%, which does not permit the selling shareholder to exercise that portion of the warrants that would result in the selling shareholder 
 and its affiliates owning, after exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation. The amounts      
 and percentages in the table do not give effect to the 4.99% beneficial ownership limitation, if applicable. The selling shareholder          
 is an affiliate of Ladenburg, a broker-dealer. The principal business address of the selling shareholder is 640 Fifth Avenue, 4th Floor,      
 New York, New York 10019.                                                                                                                     |

| 73 |

<div align='center'>PLAN OF DISTRIBUTION</div>

Each selling shareholder and any of their
pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their Ordinary Shares represented by Depositary
Shares covered by this prospectus on the principal trading market or any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder may use any
one or more of the following methods when selling securities:

| · | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; |

| · | block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the 
 block as principal to facilitate the transaction;                                                                                 |

| · | purchases by a broker-dealer as principal and resale by the broker-dealer for its account; |

| · | an exchange distribution in accordance with the rules of the applicable exchange; |

| · | privately negotiated transactions; |

| · | settlement of short sales; |

| · | in transactions through broker-dealers that agree with the selling shareholders to sell a specified number of such securities at a 
 stipulated price per security;                                                                                                     |

| · | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; |

| · | a combination of any such methods of sale; or |

| · | any other method permitted pursuant to applicable law. |

The selling shareholders may also sell securities
under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the selling